Tests a Chinese herbal medicine for low blood pressure during dialysis
Tests Guilu Erxian Jiao in adults with low blood pressure during hemodialysis.
Plain-language title generated from the registry record
Registry title: The Efficacy and Safety of Guilu Erxian Jiao in the Treatment of Intradialytic Hypotension
Key facts
- Where
- Keelung, TaiwanSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults on regular hemodialysis who have had a drop in blood pressure during dialysis sessions.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- On maintenance hemodialysis three times per week, 4 hours per session, with a history of intradialytic hypotension (low blood pressure during dialysis).
- Earlier treatment
- Must not regularly use blood pressure-lowering medicine.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Severe other illness, such as cancer, stroke or liver cirrhosis
- Cannot follow the study medicine plan
- Regular use of blood pressure-lowering medicine
This trial only enrols participants on dialysis. The registry sentence this rests on: Undergoing maintenance hemodialysis three times per week, 4 hours per session
Read by machine on 9 November 2026.
Where in Taiwan
- Keelung Chang Gung Memorial HospitalKeelung, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chang Gung Memorial Hospital
- Trial code
- NCT06980922
- Record updated
- 20 May 2025
- Original description
The goal of this clinical trial is to learn if Guilu Erxian Jiao, a traditional Chinese herbal medicine, can help manage intradialytic hypotension (IDH), a drop in blood pressure that occurs during hemodialysis in adults. The main questions it aims to answer are:Read full original descriptionShow less
The Efficacy and Safety of Guilu Erxian Jiao in the Treatment of Intradialytic Hypotension
The goal of this clinical trial is to learn if Guilu Erxian Jiao, a traditional Chinese herbal medicine, can help manage intradialytic hypotension (IDH), a drop in blood pressure that occurs during hemodialysis in adults. The main questions it aims to answer are:
1. Does Guilu Erxian Jiao reduce the frequency and severity of low blood pressure during dialysis? 2. Is Guilu Erxian Jiao safe to use in patients receiving hemodialysis?
Researchers will compare standard care plus Guilu ErXian Jiao to standard care alone to see if Guilu Erxian Jiao improves blood pressure stability during dialysis.
Participants will:
1. Take Guilu Erxian Jiao once daily in addition to standard care, or receive standard care alone, for 4 weeks, then switch treatments after a 4-week washout period (crossover design). 2. Undergo follow-up assessments at weeks 2 and 4 after each treatment phase. 3. Have their blood pressure monitored before, during (hourly), and after each dialysis session. 4. Report dialysis-related symptoms such as dizziness and fatigue. 5. Receive routine laboratory tests and safety monitoring throughout the study.
Inclusion: Age ≥ 18 years; Undergoing maintenance hemodialysis three times per week, 4 hours per session; History of intradialytic hypotension (IDH); Willing and able to provide written informed consent.
Exclusion: Inability to comply with study medication regimen; Regular use of antihypertensive medication; Severe comorbid illness, such as cancer, stroke, or liver cirrhosis; Pregnant or lactating women.